Weekly Analysts’ Ratings Changes for BioLineRx (BLRX)

Several brokerages have updated their recommendations and price targets on shares of BioLineRx (NASDAQ: BLRX) in the last few weeks:

• 12/2/2024 – BioLineRx is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/25/2024 – BioLineRx had its price target lowered by analysts at HC Wainwright from $21.00 to $9.00. They now have a “buy” rating on the stock.
• 11/24/2024 – BioLineRx is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/16/2024 – BioLineRx is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/8/2024 – BioLineRx is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/6/2024 – BioLineRx had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
• 10/31/2024 – BioLineRx is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/23/2024 – BioLineRx is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/15/2024 – BioLineRx is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

BioLineRx Stock Down 2.9 %

NASDAQ BLRX opened at $0.29 on Tuesday. The company has a current ratio of 1.52, a quick ratio of 1.49 and a debt-to-equity ratio of 2.11. BioLineRx Ltd. has a 12 month low of $0.25 and a 12 month high of $1.89. The stock’s 50 day moving average is $0.45 and its 200 day moving average is $0.60. The stock has a market cap of $23.29 million, a PE ratio of -1.32 and a beta of 1.48.

Hedge Funds Weigh In On BioLineRx

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. PVG Asset Management Corp bought a new position in shares of BioLineRx during the 2nd quarter valued at about $70,000. Atria Investments Inc lifted its position in shares of BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after buying an additional 29,193 shares in the last quarter. Finally, CVI Holdings LLC bought a new position in BioLineRx during the second quarter valued at approximately $462,000. Institutional investors own 1.56% of the company’s stock.

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.